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J
UST two years ago, I presented my first report as president of The 
Rockefeller University. There, I portrayed the distinctive chal­
lenges to the University as seen by an enthusiastic new recruit. 
With undiminished enthusiasm, I can now bring to my second re-
port a better-informed appreciation of the practical tasks of leader­
ship. This periodic stock-taking of our progress is also a re­
affirmation of our mission: to seek new knowledge as the most fruit­
ful way of achieving public benefit, as well as to sustain the traditions 
of a major scientific institution. 
The prospects for basic advances and practical "payoffs" from the 
life sciences have never been brighter. At the same time, many 
forces in the social, economic, and political environment are press­
ing on the world of research. Tremors in the global and national 
economy erode the institution's reserves and the indispensable 
nourishment of basic science from federal funds. The very advances 
of biological research in recent decades have evoked both peril and 
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promise in the public mind. Clear understanding of the linkage 
between basic discovery and applied benefits demands much more 
analysis and less passion. 
I had the privilege and joy of working at ,the research bench for 
more than 30 years before assuming the administrative tasks of 
leading a great institution and explaining it to those from whom we 
seek support. On the basis of that experience, I honor these chal-· 
lenges as a personal and institutional opportunity to respond with 
confidence and credit. This report will stress the issues raised by the 
. very complex external environment in which science today must 
play its part. In that environment, our own institution has a special 
role. In order to succeed in it, we must respond to society's expecta­
tions of science and technology and must articulate our mission in 
the system of scientific discovery, technological design, and public 
dissemination of their fruits. 
Rockefeller University: Then and Now 
This University was founded, as The Rockefeller Institute for Medi­
cal Research, some 80 years ago. It was designed to launch the 
scientific investigation of medical problems in this country and to 
match the heroic accomplishments of European medical science, 
symbolized by such "Microbe Hunters" as Louis Pasteur and Robert 
Koch. Here, too, infectious diseases took the center stage� but the 
Institute's p.rst director, Simon Flexner, also emphasized the most 
fundamental research in biological and chemical science. From its 
beginnings, The Rockefeller has always encouraged a balanced con­
vergence of clinical investigation and basic scientific activity. Many 
scientific advances had their roots in the wards and laboratories of 
The Rockefeller University Hospital. In turn, many clinical insights 
have been inspired by basic findings in biology and chemistry. 
Nevertheless, many medical institutions are experiencing the grow­
ing divergence-even alienation-of these two streams of investiga­
tion, a trend we work to forfend. 
During the early years, The Rockefeller, thanks entirely to the 
generosity of a single private donor, enjoyed a remarkable share­
initially almost half-of the total investment in medical research in 
the United States. The Institute soon achieved preeminence in the 
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scientific life of the country and furnished a model for the creation of 
similar research centers. That tradition of leadership is today a 
unique asset and responsibility, but the national investment in 
biomedical Fesearch and its allocation have, of course, changed 
dramatically. In 80 years, as measured by annual budgets in "con­
stant dollars," the University has grown by a factor of about 15, but 
medical research nationally has grown by a factor of 1,000 ( Chart 1, 
page 4). Most of the national increase and three-fourths of our 
University's were made possible by the commitment of federal 
funds, through the National Institutes of Health. Having been thus 
emulated on a very large scale, we now account for barely one per­
cent of the national expenditure in biomedical research. Our special 
impact is now expressed by the quality of our people and our distinc­
tive organization and traditions, rather than by gross level of effort. 
It in no way diminishes the Rockefeller family's role, in the 
founding and early growth of the University, that their personal gen­
erosity cannot alone shoulder the vastly expanded costs of a mature 
institution. The scope and expenses (some $55 million in 1980-81) 
of this university of science would have been unimaginable when 
the first few laboratories were opened in the early 1900s. The largest 
part of this growth is represented by numbers of laboratories, the 
wealth of scientific specialties that give the University a formidable 
profile in almost every pertinent area-from molecular and cell biol­
ogy to behavior and clinical investigation. A related investment that 
has borne valuable fruit was the introduction in 1954 of the graduate 
fellows program, the formal scientific training leading to the Ph.D. 
degree that was associated with the change of name from Institute to 
University. 
For much of the '70s, the University, like many other institutions, 
was seriously buffeted by escalating energy costs, general price 
inflation, and the slowdown of federal support. Substantial deficits 
enforced a tighter rein on expenditures, a realistic adjustment of 
self-image, and a reexamination of its central purposes. The conclu­
sion was to focus on our institution's traditional success in a bal­
anced program centered on biomedical research, like that inspired 
by Flexner. This would necessarily be extended to include studies of 
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Chart 1. Expenditures for Biomedical Research 
(Constant Dollars) 
Semi-log 
In 80 years, Rockefeller University expenditures on biomedical research have grown fif­
teenfold, total national expenditure a thousandfold. The University now accounts for one 
percent of national investment in biomedical research. 
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fro"m the mathematical and physicai sciences. Unlike many larger in­
stitutions, however, we are not hostage to large-scale fixed obliga­
tions for undergraduate education or general medical services. 
Hence, we can continue to work within a simple administrative 
structure-with individual laboratories reporting directly to the 
president-that avoids the politics and overhead of potentially 
divisive departments and separate specialty schools. 
The University's successful discipline in a time of economic in­
security has helped us to inspire the support of many private donors, 
reached by a general fund-raising effort organized barely ten years 
ago. With their help, the University has been able to balance its fiscal 
accounts and to make a realistic projection of future needs and 
resources. The model envisions that the University will continue to 
maintain its present scope and mix of programs, with 55 or 60 la­
boratory groups. A dynamic equilibrium will be achieved by balanc­
ing retirements of laboratory heads with new tenured appointments 
and promotions. Each such opportunity will be the occasion for a 
fresh examination of the University's needs and priorities. It will 
also be a time to allow for the continuing professional advancement 
of our most talented younger faculty. Within the limits of a balanced 
size, our system thus provides for evolutionary changes to meet new 
scientific opportunities, unencumbered by squatters' rights of exist­
ing specialties and departments. 
This might appear to be an unglamorous model for the future, 
building as it does on our past traditions. To the contrary, we should 
be reassured that The Rockefeller has exhibited extraordinary 
breadth and strength in its established disciplines. With a few excep­
tions, these evolutionary accommodations provide ample openings 
for fresh insights and new technical approaches. Our present size en­
courages a quality of collegial communication that would be diluted 
by rapid growth, even if this were permitted by available fiscal 
resources. 
Biomedical Research Today 
In many ways, The Rockefeller University is a microcosm of the na­
tional effort in medical research. Economic strictures in federal 
funding for basic science have been less a general cutback than an 
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end to growth in available resources. This has already collided with a 
hard-won fruition of maturing and capable scientists who have enor­
mous potential for making contributions to scientific and medical 
knowledge. 
This disparity between shrinking funds and burgeoning talent and 
scientific opportunity has intensified the competition for established 
resources and positions. It has eroded the stability of support for 
research programs. It aggravates the anxieties of investigators about 
their opportunity to continue research. It tends to immobilize them 
in location and in scientific interests. It impels them to spend enor­
mous amounts of time and emotional and intellectual energy in en­
trepreneurial ("grantsmanship") activities at the expense of their 
central passion and responsibility. By maintaining a stable setting for 
a faculty of excellence, The Rockefeller University makes an ex­
traordinary contribution in substance and by example. The ebb and 
flow of government support and the rigidities it imposes (in the 
name of accountability) are a major source of the pressures. Hence, 
it is the University's autonomy as a privately supported institution, 
that bridges the financial gaps and crevices left by spasmodic public 
funding. Not for many years has it been possible for any institution 
to match from other sources the federal support it received for the 
major portion of its research expenses. However, even modest gen­
eral funding for this bridging of contingencies greatly amplifies the 
efficacy of government funding. 
The University has a �ost successful tradition of supporting and 
developing creative leaders in research. Hence, programmatic orien­
tation tuned to trends in research support takes second place to sus­
taining an effective style of research career. We aim to furnish first­
class investigators the freedom to set their own directions and deter­
mine their own research objectives. For the University to continue 
to do so will require extraordinary effort in the face of global 
economic difficulties and their impact on government, corporate, 
and individual philanthropic investment in science. The commit­
ments made by the University to its faculty and major programs span 
decades. The funds to meet them must be anticipated and provided 
for over a much longer period than their sources can be accurately 
foreseen. The most reliable long-term source of funds-the real in-
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come from endowment-covers scarcely a fourth of our operating 
budget. However, this is the margin that enables us to underwrite 
our plans against the uncertainties of year-to-year support. 
No single measure of inflation assures an authentic picture of the 
institution's financial standing in a single year. For example, the re­
cent high interest rates resulted in a temporary rise in our revenues. 
On the other hand, many of our future expenses will, no doubt, in­
crease in the same measure, but will not all be reflected in a single 
annual statement. In addition, the Uni':1ersity is just now catching up 
with many long-delayed maintenance tasks and laboratory renova­
tions. However, our ten:..year projections-premised on sustained 
effort in our development program-show a continued equilibrium 
of income and expenditures. These forecasts are the most realistic 
tools for long-range planning. Table I on page 8, prepared by David 
J. Lyons, the University's vice president and controller, is another
effort to review the stability of our endowment reserve through the
turbulence of the last decade. The outcome is, of course, highly sen­
sitive to conflicting measures of real costs of research, but it does
provide reassurance that the University can manage its affairs suc­
cessfully even through such storms.
Sustaining Public Confidence 
Despite the leveling off in federal funding, biomedical research still 
enjoys a privileged place in the expectations of the public. The NIH 
and similar programs were almost the only ones, besides national 
defense, to escape crippling wounds in the 1982 federal budget. 
Continual strictures in federal expenditures have, however, made 
deep inroads in the integrity of many programs in research and gra­
duate training. 
We have a special opportunity and obligation to sustain public 
confidence, and the University's concern for critical scrutiny of our 
research converges with that of the larger society. This is directly re­
lated to the ongoing renewal of our faculty. The premise of our sys­
tem of career appointments is the most stringent selection of those 
who receive them. In exchange for that stringency, the University 
gives those appointed the widest encouragement and the support 
they deserve as leaders in the difficult paths of scientific discovery. 
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That so much responsibility is delegated to the laboratory heads is 
precisely why these choices must be so closely scrutinized. The first 
criterion is, of co�rse, the investigative excellence of the candidate. 
Then we may optimize our choices with respect to the fit of a candi­
date to the institution's primary mission as a biomedical research 
center and a community of scholars, and to other dimensions of 
campus life. 
No one can accuse- this institution of making its choices on the 
basis of parochial relevance. Historically, the University's most dis­
tinctive characteristic has been the conviction that our explorations 
need but go deep enough for discovery to relate to profound human 
benefit. Nonetheless, we must recognize that outside forces often 
demand short-term yields that are simply unachievable: least of all 
by insistence on "targeted" research. The NIH budget is, in fact, the 
largest federal commitment to basic science: a preponderance that is 
socially justified by benefits to public health that derive from the 
most fundamental knowledge of living systems. This is not a univer­
sally recognized linkage. For one thing, the partial successes of semi­
empirical medicine with vaccines, antibiotics, and psychotropic 
medications have obscured how incredibly crude our insight is about 
how and why these interventions work-how far medical scientists 
are from the kind of understanding that unites the physicist and the 
integrated-circuit design engineer. It is not lack of ingenuity or dili­
gence; it is the inherent complexity of living organisms-above all 
the human-that frustrates our moving medical care and preventive 
health into the realm of design enginering. To meet such an ambi­
tious goal entails still more basic research, on a scale that would 
remain a small percentage of expenditures on health care. Despite 
many isolated improvements, the overall limits to our success in 
dealing with cancer, even during the last decade, illustrate the short­
fall in our needs for basic biomedical knowledge. 
In any event, there remains a needless and damaging alienation 
between the adherents of this view and those who seek to accelerate 
application of the advances we have made. The alienation arises, in 
part, from the understandable anxiety of basic scientists about the 
seeming social ambivalence regarding the support of their efforts. 
Further confusion stems from the fact that the practical dissemina-
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tion of health technology is not in the hands of scientists; but is the 
preserve of two other communities-the medical practitioners and 
the pharmaceutical industry. These two groups are closely coupled 
to a health economy with very large revenu.es. Basic research is not. 
Considering the attendant pressures so evident on the public scene 
today, it would be a mixed blessing if basic research were so coupled. 
The research laboratory is not well organized to get "results" in a 
sphere that depends more on market analysis than it does on 
scientific understanding. 
Equally unfortunate is the quarrel between some advocates of 
public policies for preventive health and of rational medicine. There 
is no controversy that disease-prevention is vastly preferable to the 
most sophisticated of cures. It is also true that important improve­
ment to personal health is achievable by commonsense attention to 
lifestyle (e.g., diet, smoking, use of alcohol and other drugs, exer­
cise, and sleep). While we have long since set aside prohibition as an 
answer to alcohol abuse, there remains a widely held attitude that 
disease is the penalty of sinful life. The fact remains that many 
heart-disease victims are not obviously stigmatized by their lifestyle, 
and that the health penalties of aging will be with us regardless of 
personal hygiene. The delineation of the most important and useful 
elem_ents of personal behavior and of environmental protection is a 
cogent challenge to the most sophisticated biomedical research. So 
also are the factors that entrain people into behaviors they well know 
to be self-destructive. 
We may recall that, in the last century, cholera was believed to be a 
visitation for sin� many still place sexually transmitted diseases in 
that category today. Whatever the merits of these views as moral 
philosophy, they have been far less productive of material health ad­
vances than an understanding of the biology of the causative organ­
isms and development of specific measures against them (Chart 2). 
A Question of Balance 
Yet it is uncertain whether scientists have been able to articulate a 
sufficiently persuasive response to the taxpayers' expectations. Both 
in rhetoric and in policy, we face a delicate task of balance for our 
own institution, to maintain its distinctive genius, and to fulfill the 
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Chart 2. Major Causes of Death in the United States 1900-1975 
1900 
Crude Death Rate 
16.2 per 1,000 
1940 
Crude Death Rate 
10.6 per 1,000 
1975 
Crude Death Rate 
9.0 per 1,000 
Causes of death: In these crude death rates, the largest factor in the shift is the "conquest" 
of infectious disease and the resultant rising age level, as shown by the increase in cancer 
and heart disease. 
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mandate of our motto: pro bono humani generis. Of course we should 
eschew applied research tasks to which we are ill-suited. However, 
there is no contradiction between hewing to our pursuit of basic 
knowledge and educating ourselves about t�e realities of disease as a 
rich source of puzzles of biological behavior that stimulate our 
theoretical imagination. Nor should this mandate for a well-knit in­
stitution be confused with intrusive and unrealistic demands on in­
dividual investigators. We may again look to Simon Flexner's initial 
conception of a balanced institution encompassing an unbroken 
spectrum of basic to clinical investigation, from the laboratory to the 
research-hospital ward. Many universities and medical schools have 
jeopardized that balance, and weakened support for and useful in­
tercommunication with the basic sciences, by assuming the obliga­
tions of large teaching hospitals and the related heavy and self­
aggravating burdens of service and practice. This development 
deepens the imperative that we sustain The Rockefeller University 
as a place where clinical investigation can be significantly represent­
ed without swallowing up the entire research effort. That clinical 
component, embracing research on distinctive problems of human 
biology and pathology, makes it impossible to put out of mind the 
grievous ills which we have an obligation to alleviate. It also alerts 
our scientific community to pathobiological processes, information 
that time and again has opened our eyes to previously ignored 
phenomena of the most fundamental biological importance. 
Under the leadership of Attallah Kappas, The Rockefeller Uni­
versity Hospital is engaging in a significant renascence of its pro­
grams. Notable are major new efforts in endocrinology and derma­
tology. The focus of interest in endocrinology in the laboratory 
headed by Jack Fishman is on the biology of steroid hormones with 
particular emphasis on their role in human phy�iology and patho­
physiology. The laboratory of cutaneous biology and investigative 
dermatology, under D. Martin Carter, will explore fundamental 
mechanisms that are operative in the disabling skin diseases. 
Complementary Institutions 
In the University's continuing effort to maintain an optimum bal­
ance in its research efforts, we have a considerable advantage in the 
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close proximity of two major patient-intensive hospitals-Memorial 
Sloan-Kettering Cancer Center and The New York Hospital-Cornell 
Medical Center. The development of a dermatology program at our 
hospital was made possible by opportunities for research collabora­
tion with New York Hospital-Cornell. Similar collaborations are 
under discussion with the Population Council's Biomedical Re­
search Division, whose laboratories are situated on our campus, and 
with Memorial Sloan-Kettering. 
It is in clinical research that our strengths and interests most evi­
dently complement those of our neighbors. We are also seeking 
every other means to further the maximum good from our collec­
tive human and physical resources. The three institutions at the in­
tersection of York Avenue and East 68th Street are-by world 
standards-a formidable concentration of medical interests, ser­
vices, and science. Increased communication and collaboration 
within this complex will go far to ensure that our scientific efforts are 
informed by human health needs. In turn, no opportunities will be 
overlooked to go from research advances to practical application at 
the earliest occasion. In addition, choices of programs to be further 
emphasized can be made in the light of existing strengths within the 
complex. 
The metropolis has a rich academic culture at many other places , 
as well, and as a specialized center we are particularly grateful for that 
environment. 
Public Health Problems 
If there is a significant weakness or imbalance in the complementary 
efforts of the three institutions to address human concerns, it is re­
lated to certain widespread problems of public health and preventive 
medicine. This imbalance is national, even global,- and stems from 
the relative poverty orfunding available for research programs not 
related directly to an existing and potentially remediable disease. 
Especially impoverished is work on the parasitic scourges, which pri­
marily attack the populations of developing countries, locked in a vi­
cious cycle of ill health and low economic productivity. 
In the latter category, we are continuing our traditional support of 
work in parasitology with a particular view to unifying it with modern 
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developments in molecular and cell biology. These will have most 
exciting, as well as useful, applications for such tropical diseases 
as malaria, trypanosomiasis, schistosomiasis, leishmaniasis, and 
filariasis-scourges happily almost unknown in this and other of the 
more developed countries, and for that reason grossly neglected. It
is with particular gratification that we can announce the recent ap­
pointment of George Cross, a molecular parasitologist, who will 
come here from England. We will also be working closely with The 
Rockefeller Foundation's global network on the "Great Neglected 
Diseases," for example in the organization of summer laboratory 
courses at the Woods Hole Marine Biological Laboratory. 
In the category of protective health problems not directly related 
to disease, a vitally important research need is an effort to put en­
vironmental toxicology on a scientific base. The last decade has seen 
a dramatic awakening of public concern over the injurious effects of 
certain substances. This is a long-overdue reaction to neglect and ig­
norance of the power of an industrial society to pollute even the glo­
bal environment. It has been accompanied, however, by stringent 
regulatory controls that threaten to hinder industrial development at 
a time when our economy is already under heavy pressure. These 
costs may be unavoidable in the light of potential hazards to public 
health, but in the present state of our knowledge they are too often 
inflicted on the basis of alarm rather than proven assessment of ha­
zard. This unproductive impasse cannot be a stable basis for national 
policy, and any improvement must be based on sharper tools for 
predicting the actual hazards to human health from exposures to 
substances for which some alarm has been elicited from limited la­
boratory findings. That the Congress has singled out saccharine for 
exemption from the prevalent standards of food-additive regulation 
illustrates the arbitrariness of judgment that now prevails. 
Toxicology, as an academic discipline, has suffered sharply from 
being too tightly coupled with routine regulatory test demands. In 
fact, as a scientific challenge, toxicology is intimately connected with 
the most intricate issues in molecular and cell biology. Many of the 
most basic discoveries in metabolism and in neurobiology stem 
from the investigation of toxic effects of particular substances. With 
the gratifying endowment of The R. Gwin-Follis-Chevron Chair by 
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the Standard Oil Company of California, we are in the position to 
seek the leadership for a major program in comparative toxicology. 
The Basic Sciences 
( 
The areas of clinical and public-health science just surveyed have, of 
course, the most immediate relationships to the practical problems 
that are the justification for public investment in The Rockefeller 
University. In danger of being overlooked is the intricate connection 
between these public fruits and the basic scientific work that fully 
defines our mission. Historically, the University has made innumer­
able and invaluable contributions to public health. These include the 
development of vaccines, the transfusion and preservation of blood, 
the monitoring of body metabolism in pathological states, research 
underlying organ transplantation, and a host of other therapeutic 
techniques. Such advances are indispensable to the really important 
triumphs of medicine, but only the most sophisticated of observers 
could know the distant origins of such triumphs in the laboratories 
of the biochemist, molecular biologist, or biophysicist. The basic 
contributions are overshadowed by the communities of other tech­
nologists and practitioners, who interface much more directly with 
the public. 
A notable example is the discovery of the biological significance of 
DNA, brought to light in 1944 by Oswald Avery, Colin MacLeod, 
and Maclyn McCarty (page 16). The historical links between that 
momentous discovery and the current technological breakthroughs 
in recombinant DNA methods and genetic engineering are unambi­
guous and well known within the scientific field. However, it would 
be hard to find a mention of them in the prospectuses for new indus­
tries spawned by DNA science� nor is there any direct way that the 
University can be rewarded, precisely because this was such a funda­
mental discovery. Could the interval of more than 35 years between 
discovery and invention have been shorter? Probably not, in view of 
the extensive superstructure that had to be built on the initial 
finding. 
When it comes to medical applications, I have sometimes asked, 
during the past decade, whether DNA science has yet made a contri­
bution to medical practice to match the revolution it had brought 
Oswald T. A very Colin M. Macleod Maclyn McCarty 
STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE 
INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES 
INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC Acrn FRACTION 
ISOLATED FROM PNEUMOCOCCUS TYPE III 
BY OSWALD T. AVERY, M.D., COLIN M. MACLEOD, M.D., AND 
MACLYN McCARTY,* M.D. 
(From the Hospital of The Rockefeller Institute for Medical Research) 
PLATE 1 
(Received for publication, November 1, 1943) 
Biologists have long attempted by chemical means to induce in higher 
organisms predictable and specific changes which thereafter could be trans­
mitted in series as hereditary characters. Among microorganisms the most 
striking example of inheritable and specific alterations in cell structure and 
function that can be experimentally induced and are reproducible under well 
defined and adequately controlled conditions is the transformation of specific 
types of Pneumococcus. This phenomenon was first described by Griffith (1) 
who succeeded in transforming an attenuated and non-encapsulated (R) 
variant derived from one specific type into fully encapsulated and virulent (S) 
cells of a heterologous specific type. A typical instance will suffice to illustrate 
the techniques originally used and serve to indicate the wide variety of trans­
formations that are possible within the limits of this bacterial species. 
Griffith found that mice injected subcutaneously with a small amount of a living 
R culture derived from Pneumococcus Type II together with a large inoculum of 
heat-killed Type III (S) cells frequently succumbed to infection, and that the heart's 
blood of these animals yielded Type III pneumococci in pure culture. The fact that 
the R strain was avirulent and incapable by itself of causing fatal bacteremia and the 
additional fact that the heated suspension of Type III cells coutained no viable or­
ganisms brought convincing evidence that the R forms growing under these condi­
tions had newly acquired the capsular structure and biological specificity of Type III 
pneumococci. 
The original observations of Griffith were later confirmed by Neufeld and Levin­
thal (2), and by Baurhenn (3) abroad, and by Dawson (4) in this laboratory. Subse­
quently Dawson and Sia (S) succeeded in inducing transformation in vitro. This 
they accomplished by growing R cells in a fluid medium containing anti-R serum and 
heat-killed encapsulated S cells. They showed that in the test tube as in the animal 
body transformation can be selectively induced, depending on the type specificity 
of the S cells used in the reaction system. Later, Alloway ((,) was able to cause 
* Work done in part as Fellow in the Medical Sciences of the National Research 
Council. 
Opening page of the DNA paper, published in 1944 in TheJournalofExperimemal Medicine 
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about in biological research. To pursue this question, we should re­
view the development of biomedical research of the past century. 
About a hundred years ago, the germ theory of disease was the 
principal foundation of modern scientific medicine. Antisepsis 
saved innumerable lives in childbirth and in surgery. Elementary 
hygiene and protection of food and water supplies from contamina­
tion saved even more. As bacteria were grown in pure culture and 
identified as specific agents of disease, vaccines could be developed. 
The aspects of applied medical microbiology concerned with bacteria 
reached their zenith in the 1950s with the wonder-drug antibiotics, 
which have totally reversed the odds in the battle between afflicted 
patients and many infectious invaders. The development of polio 
vaccines soon after was a similar culmination, in the public's aware­
ness, of the application of basic findings in virology to the conquest 
of infectious diseases. 
The human benefits from scientifically informed attack on the 
problems of infectious disease are incalculable. Lamentably, we 
have not seen the last of threats to health from microbes and 
viruses. Antibiotic-resistant pathogens evolve in the most trouble­
some way, and may yet provoke major epidemics difficult to control. 
Vaccines for pneumonia, having been preempted almost 40 years 
ago by sulfa drugs and antibiotics, have been dusted off the shelves 
and are reemerging as a delayed fruit of the Rockefeller Institute 's 
research. Most virus infections still defy systematic treatment: only 
with a clear understanding of the genetic structure and evolutionary 
potential of the influenza virus, and of its protein structure, can we 
develop fully effective prevention for this debilitating disease, which 
may affect tens of millions of people in an epidemic year. 
This extraordinary success of medical science between 1880 and 
1950 was the main inspiration for vigorous national support of 
research modeled largely on The Rockefeller Institute: the federally 
funded programs of the National Institutes of Health. However, 
with these same dramatic successes against infections, our priority 
health problems have shifted to heart disease, cancer, and psychia­
tric illness. The inherent intricacy of these problems, which are root­
ed deeply in the molecular and cellular structure of the human or­
ganism, outreaches the existing base of applicable scientific 
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knowledge. This ignorance has frustrated the building of a theoreti­
cal program for the control of these killers comparable with the ad­
vances in the golden age of bacteriology to which Rockefeller scien­
tists made such historic contributions. 
This frustration is partly obscured by a number of valuable piece­
meal advances in all of these fields, by the proliferation of high­
technology diagnostic machines, and by the development of 
scientifically trained, sophisticated specialties to make these accessi­
ble to patients. This technological revolution has also carried a heavy 
price tag, and some political pressure for cost-reduction that would 
better be directed to benefit-improvement. The training of these 
specialists has been the main contribution of academic medical insti­
tutions to today's "half-way technology" in medical care. Most of the 
important new drugs of the past 30 years have been discovered 
through empirical, not rational, procedures and in industrial, not 
academic, laboratories. Empirical as they are, these discoveries also 
depended on an infrastructure of scientific knowledge to calibrate 
how drugs like aspirin, chlorpromazine, or thiazides can best be em­
ployed. Equally important, a host of spurious remedies would be 
firmly planted in our medicine cabinets without the certification of 
efficacy and safety that must be informed by the most rigorous 
scientific judgment. 
This perspective on recent medical science is a controversial one. 
It deviates from the optimistic forecasts of the 1950s and from the 
"crusade against cancer" of the '70s that seemed to promise an early 
solution to these pervasive health problems. Many believe in a more 
rational reductionist approach to medicine that would be firmly 
based on rigorous scientific knowledge, and would give academic la­
boratories greater credit for practical health advances. In fact, I 
firmly espouse that view; my critical reflections have to do with the 
time-scale of these expectations, and with an authentic reading of 
the actual history of the last 30 years. My greatest fear is that 
scientific insight is dissynchronized with public understanding. In­
stead of sensing the remarkable opportunities through which sci­
ence can contribute to society-opportunities that, historically, oc­
cur in cycles-the public may become disillusioned; the result could 
be retrenchment of research support. 
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The current cycle is impelled by the most fundamental of biologi­
cal sciences, the study of DNA and proteins. It can now be estimated 
that the human body contains some 100,000 different and distinct 
categories of proteins. As organisms, we are a hundred-or a 
thousandfold more complex than the microbes we target in warding 
off infectious disease. Today, we have some skimpy knowledge of 
perhaps 1,000 of those human proteins: we have scratched the sur­
face to a depth of one percent! Almost everything we attempt in ra­
tional medicine is connected with the structure and behavior of pro­
teins. We stumble in a dark cave, guided more by intuition and trial­
and-error than by a readable topographic map. Our hopes for radical 
interventions to prevent or reverse such complex processes as canc­
er or aging can scarcely outpace that knowledge. 
Until about ten years ago, our methods enabled only crude 
guesses at these orders of complexity. Today, news of DNA per­
vades the stock mark.et. It may be woefully ill-informed in detail, but 
it has accurately mirrored the confidence and energy of investigators 
who are rapidly developing these new biological tools at an escalating 
pace. No prophecy can be safe: but all of the.crucial disease threats to 
human life now fall within the reach of fundamental molecular and 
cellular investigation. Just this scientific base remains the main core 
of The Rockefeller University's programs. If we can sustain our 
courage, critical candor about the historic stages of development of 
medical science, and public confidence, we can indeed complete a 
new cycle of health benefit to match that of the heroic conquest of 
bacterial infection. To underestimate either the hurdles or the fruits 
will vitiate our effort. 
The Spectrum of Science 
The breadth of the University's commitment to fundamental biolo­
gy defies compact summary. It can be found in the reports of the ma­
jority of our laboratory groups. Their work ranges from the ultra­
structure and biophysics of cell membranes to the neuronal basis of 
bird song. This institution has been designed to be of such a size and 
scope that it can just encompass almost every important field of bio­
logical investigation, and is s�ructured so as to facilitate communica­
tion among its specialists. 
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A few words, then, about several movements for change within 
this well-established setting. The neurosciences have been an im­
portant tradition at Rockefeller University. For example, its second 
director, Herbert Gasser, was a pioneering,neurophysiologist who 
introduced the oscilloscope into that line of research. For the last 20 
years, a fertile intersection of neurophysiological research with the 
integrative outlook of the behavioral scientist has been the contribu­
tion of Carl Pfaff mann and the group he helped to develop at the 
University. Recent and imminent retirements now impel a special 
emphasis on renewal in this general field, and we have been mar­
velously assisted by the benefactions of the Astor Foundation. In 
my next report, I hope to announce several recruitments. 
We can already take pleasure in the move now underway to our 
campus of the Neurosciences Research Program (NRP), formerly at 
Boston, Massachusetts, and presently directed by Vernon B. 
Mountcastle of The Johns Hopkins University. The NRP is spon­
sored by the Neurosciences Research Foundation under the chair­
manship of William T. Golden, a member of The Rockefeller 
University Council. One of the major activities of NRP at The 
Rockefeller University is a new Neurosciences Institute� Gerald M. 
Edelman of our faculty, who serves as scientific chairman of NRP, 
will be its director. Working with Dr. Edelman, a scientific advisory 
committee directed by W. Maxwell Cowan of the Salk Institute will 
extend invitations to brain scientists the world over who wish to use 
the facilities of the Institute. Visits by these scientists will enrich 
communications here and elsewhere and help us to understand the 
challenging problem of the basis of higher brain function. 
Similarly, the University recently reaffirmed its longstanding in­
terest in the lessons to be learned from the botanical world. In the 
new laboratory of Nam-Hai Chua, DNA methodology has been ap­
plied to study fundamental aspects of protein synthesis that are im­
portant to the efficiency of plant photosynthesis. This research could 
have an important bearing on the improvement of the productivity 
of major crop plants and testifies to the continued vigor of a universi­
ty tradition pioneered by Louis 0. Kunkel, Wendell Stanley, and Ar­
min Braun. 
Advances in molecular biology have gone so far that one possibly 
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overenthusiastic commentator has bewailed the looming lack of un­
solved scientific problems. That may be for the next millenium; 
meanwhile the translation of genetic blueprints into the fabric of the 
organism, i.e., the problem of development, is one of our most ur­
gent and exciting challenges. We are gratified at the further rejuve­
nation of our research programs in this field through the recruit­
ment of Robert Roeder, a world-esteemed colleague who may well 
be said to substantiate the traditions established at our founding by 
Jacques Loeb. 
Some of the proudest accomplishments in the University's histo­
ry have concerned the structure of enzymes-their chemistry as 
protein chains of amino acids, and how their shape endows their 
near-miraculous role in metabolism. These structures are the work­
ing machinery of the cell, the material product of the DNA genetic 
blueprints. To sustain our leadership in this field, we are gratified 
that another world-eminent figure, Emil Thomas Kaiser, will short­
ly be joining us. His research to date has been notable in its applica­
tion of rigorous physico-chemical measurement and construction to 
fundamental and to practically important biological problems. 
Physical, Mathematical, and Computer Sciences 
Mathematical reasoning is the ultimate tool of rational human 
discourse. We cannot truly claim theoretical understanding of a na­
tural phenomenon until we apprise it well enough to express our 
models in mathematical notation. Then, and not before, they are 
amenable to formal verification and search for inconsistencies and 
further implications. To a large degree, physics and chemistry have 
been unified through this process. By allqwing us to approach 
rigorous calculations of the shapes and attractive forces of organic 
molecules, these studie� have already helped to- place molecular 
biology and pharmacology on a more sturdy theoretical basis. 
Mathematical calculations are also beginning to help us manage the 
complexity of the nervous system: How else could the human brain 
hope to understand its own complexity? Finally mathematical statis­
tics is an indispensable underpinning for testing hypotheses in ex­
perimental biology and medicine, and especially for studies in popu-. 
lation biology and epidemiology. 
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Nevertheless, much of contemporary biological research is 
beyond the reach of mathematical theory: the rules do not lend 
themselves to precise expression with existing algebras and in the 
present state of our knowledge. Rapid advances in molecular biology 
are beginning to allow us to treat living phenomena with greater 
rigor, and there is then some hope of the feasibility of a more 
mathematical theory for biology that should help knit together the 
various branches of study, both within biology and in its relation­
ships to physics and chemistry. 
It is not easy to prescribe how to reach such a goal, but The 
Rockefeller University with its capability for interdisciplinary study 
has a speci�l responsibility. We are in the course of an analytical 
study of the place of mathematics here, whose outcome cannot be 
anticipated, especially as limited resources will oblige us to select 
only the most persuasive of a group of desirable options. The issues 
to be considered must include: a) What is the current status of 
mathematical biology, and who are its most effective exponents? b) 
How can we best expand our efforts in the physical sciences, most 
effectively to bridge the gap between the small, superb group in 
high-energy physics and the main body of research that deals with 
molecular rather than subatomic phenomena? c) How to take ad­
vantage of the explosive developments in computer science and 
technology? And all of these in a fashion that engenders an organi­
cally effective, overall program here. 
The Rockefeller University has been among the pioneers in 
biomedical electronic instrumentation� it is then ironic that it should 
have been relatively tardy in the applications of general-purpose 
computer technology and information science. This can be under­
stood in light of the extensive framework of engineering and other 
technological capabilities that are centered outside the biomedical 
sciences, and can only be found at the largest general university 
centers like Stanford and MIT. We cannot indefinitely ignore these 
developments, especially as the costs of computing hardware, and 
general access to computing centers through digital telecommunica­
tions, bring these capabilities within our reach. Besides the well­
established role of computers in mathematical calculation, the link­
age of computers with communications can greatly advance library 
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information services, administrative management, personal sci­
entific interactions, and the individual's own extended memory. In a 
word, this technology is indispensable for the kind of institution we 
describe ourselves to be. 
To date, we have taken only the first steps in establishing a sophis­
ticated computer network, with the installation of modest-sized 
DEC (PDP-11/70 and V AX-11/780) machines and a campus net­
work through our telephone lines. This offers document-processing 
as well as mathematical-calculating services, and during the next de­
cade should become the most robust medium of personal communi­
cation, as well as information-storage and -retrieval on the campus. 
This document, for example, is one of the first of our university 
publications to be fully drafted, edited, and prepared for print on our 
system. We are most grateful to Bell Laboratories, Inc., for their as­
sistance in mounting the UNIX™ operating system, which has been 
designed to meet a similar range of needs. 
Relations with Industry 
We are entering an era when the industrial sector is bound to be 
more important in university policy for many converging reasons. 
The leveling of federal support is only the most superficial of these. 
Perhaps the most important is the national need for the revitaliza­
tion of our economy through technology, and of individual produc­
tivity through the enhancement of human skills. Industrial funding 
is now indispensable for not-for-profit institutions. In addition, new 
forms of tangible cooperation, through the convergence of comple­
mentary skills and backgrounds, can offer many other advantages. 
Yet, there is an undeniable and intrinsic source of conflict, namely 
between the proprietary interest of a single firm and the public 
responsibilities of the institution. However, this conflict can be 
managed and contained to achieve many countervailing benefits. 
The University should not forget or confuse its distinctive role as a 
fount of fundamental knowledge. Nevertheless, it can be a clearly 
identified partner with sponsors, if mutual interests serve practical 
purposes. But it must not become a captive of particular interests, 
lest it fail its public responsibilities and antagonize other potential 
partners. 
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These are not easy issues to resolve, and relations with industry 
will continue to demand the most careful deliberation and max­
imum understanding among faculty, president, and trustees. For­
tunately, the organization of this University into distinct labora­
tories enhances our flexibility in dealing with industrial sponsors. 
Each laboratory is a unit large enough to be important in its field of 
research, yet small enough for agreements to be negotiated respon­
sibly� as a result, the funds involved in a given transaction with any 
one laboratory will not be thought to distort the institution's overall 
priorities. The University's role is to be a responsible agent, to pro­
tect the faculty against undue intrusion on academic prerogatives 
and freedom, to ensure that external agreements do not abuse other 
elements of the University, and to negotiate in ways that do fairly re­
ward the institution. Above all, we have the pro bona responsibility 
of helping to accelerate useful applications of scientific advances. 
Life on Campus 
The daily stresses that affect the life of science are ameliorated at 
The Rockefeller University by the spirit of the campus community. 
The tranquil beauty of the campus, especially in contrast to the stri­
dency of the city, is an irreplaceable asset. 
These surroundings are the setting for another unmatched 
asset-a staff with a truly impressive range of skills and talents and a 
rare level of dedication. Probably only those in this research com­
munity can ever know how much the University's success rests on 
the skills of the entire staff-office workers and instrument-makers, 
nurses and gardeners and technicians, engineers and cleaners. Their 
competence and pride, and in many cases their ingenuity and even 
heroism in the services they provide, have been extraordinary over 
the years. 
Perhaps the most intangible of our attributes is the quality of com­
munication within our group of scholars. The Rockefeller Universi­
ty was designed for interdisciplinary efforts, and for the intellectual 
revolution that can attend them. This kind of effort does not come 
naturally. In various ways it flies in the face of many structural obsta­
cles in contemporary institutions. Witness just the fragmentation of 
federal support via splintered project grants. When the University 
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was much smaller and more tightly directed, it was far easier to sus­
tain a coordination of mutual interest. Our laboratory heads, who 
number fewer than 60, can more readily sustain an institutional 
orientation. Our junior faculty and fellows number some 500, and 
their responsibilities to an individual laboratory may add to the 
difficulty of relating to the overall community. A number of devices 
are in play to help provide a reasonable balance of focus and perspec­
tive for the professional activities of this group. For example, a 
weekly colloquium is a long-standing, traditional forum for the en­
tire University. Nevertheless, so much of our energy during the past 
decade has been consumed by fiscal crises that we should now seek 
further measures to help us function as an intellectual community, 
with the utmost cross-stimulation and criticism. The overall size of 
an institution may be an intrinsic obstacle to that easy intimacy of 
minds, but this is a task that must engage all of the wisdom of the 
campus. As we succeed, our campus community will continue to 
stand as a model for collegiality of scholarship. 
Financial Trends 
Financial operations for the year ended June 30, 1981, showed im­
provement from the previous year and, for the second consecutive 
year, revenues exceeded expenditures. Table 2 summarizes reve­
nues and expenditures, including capital budget operations, for the 
last three fiscal years. 
The amounts in Table 2 do not include the approximately 
$26,550,000 in net additions to endowment and similar funds dur­
ing the three-year period. These funds provide additional invest­
ment income (see line 3, Table 2) which helps to offset the decline in 
purchasing power of the current investment income. 
Chart 3, page 27, shows the trend in revenues for the last ten 
years. There are three basic sources of revenues: investment in­
come, private gifts and grants, and government grants. The "other 
revenues" are primarily associated with the self-balancing opera­
tions of housing, food service, and The Rockefeller University 
Press. Development efforts were first begun in 1972; the subse­
quent growth in private gifts and grants and the increased invest­
ment income from additions to endowment funds have provided 
Chart 3. Revenue Sources 




























28 The Rockefeller University 
the opportunity to manage the large increase in governmental funds 
without losing flexibility or control of institutional priorities. 
Chart 4 shows the different components of revenues and expendi­
tures with the related percentages for the fiscal year ended June 30, 
1981. 
The market value of endowment investments at June 30, 1981, 
was approximately $270 million. Independent analyses of our port­
folio by Merrill Lynch over an extended period of time show that our 
professional management has produced exceptionally good results 
when compared with other funds with similar objectives. 
Financial Outlook 
The greatest threat to our financial operations at the present time is 
the uncertainty about the level of governmental funding which pro­
vided more than $21 million in fiscal 1981. The University currently 
has in excess of 250 active federal grants, and nearly every one of 
our laboratories will be affected by federal budget cuts. 
Provision-for capital expenditures in the years ahead is an urgent 
concern. A continuing need is to obtain more sophisticated equip­
ment, to modernize support functions, and to comply with regulato­
ry requirements that affect the operations of research laboratories. 
Beginning in 1982, we will modernize older buildings as we start 
several major new laboratories. The "start-up" costs of launching a 
new laboratory are significant. We also will soon have to reckon with 
the very large financial burden of additional housing for our faculty. 
It is almost impossible to obtain governmental funds for these capi­
tal expenditures, so we look primarily to private donors for our 
essential needs. 
The University operates on a ten-year financial plan that is updat­
ed three times each year for review by the Board of Trustees. The 
most recent projections show that we should again operate in the 
black in fiscal 1982, but we are projecting a deficit in fiscal 1983 be­
cause of the start-up costs of new laboratories. In effect, we will be 
using most of the reserves built up in our operating budgets during 
the last two years. Projections for the balance of the ten-year period 
reflect an intent to maintain our programs at roughly the present lev­
el and to conduct financial operations at break-even. 
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The attainment of these projections will certainly require great 
effort and some good luck in the face of probable levels of inflation 
and likely reductions in governmental funding. But I am confident 
that the quality of our work will continu� to attract the support 
necessary to perform our mission. 
Development Program 
The detailed objectives for the current ten-year, $150-million 
Development Program, which began in July 1978, are shown in 
Table 3. Progress by June 30, 1981, the end of the third year of the 
program, was $67.7 million, including $59 million in new gifts and 
·pledges received since July 1978 and $8. 7 million in payments on ear­
lier pledges. This represents 45% of the ten-year goal. Not included
in the total is an additional $11.9 million in trust and estate commit­
ments.
Nearly half of the ten-year total, $71 million, is being sought for 
additions to endowment. I am therefore especially pleased to report 
that $40.1 million of that $71 million has already been pledged. This 
has provided significant added security for our financial outlook. 
In my previous report, I announced the award by the Rockefeller 
Brothers Fund of a five-year, unrestricted grant of $15 million with 
provision for an additional $7.5-million challenge grant if two condi­
tions were met by December 31, 1986: that the University raise $25 
million in new endowment and that we match the $7 .5 million RBF 
challenge grant by additional contributions to endowment from gifts 
or other sources. 
I am pleased to report that by June 30, 1981, we had met and ex­
ceeded the above conditions five years ahead of the deadline {in­
cluding allocation of the original $15-million grant to endowment). 
Subsequent discussion with officials of the Rockefeller Brothers 
Fund indicates that we may anticipate early payment of the challenge 
grant. 
On the basis of the performance of our Development Program 
since its inception in 1972, it is tempting to be optimistic about the 
future. However, there are some major concerns. One of them, as I 
have mentioned, is the reduction in federal funding of basic 
research. Another is the impact of the 1981 Tax Reform Act, which 
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Table 3. The Rockefeller University 
Ten-Year Development Program, July 1978 to June 1988 
ENDOWMENT 
Amount 
20 Endowed Professorships: ........................... $25,000,000 
Fellowships: 
10 University Fellowships ............... $ 8,000,000 
10 Clinical Fellowships ................. ·. 8,000,000 
20 Postdoctoral Fellowships .............. 10,000,000 
50 Doctoral Fellowships ................ 20,000,000 46,000,000 
Total for Endowment ............................ $71,000,000 
PROGRAM SUPPORT AND CAPITAL PROJECTS 
Restricted Program Support 
Fundamental investigations, 
including molecular and cell 
biology, the neurosciences, 
parasitology, reproductive 
biology, immunology, toxicology ........ $35,000,000 




medicine, pharmacology .............. 20,000,000 $55,000,000 
Unrestricted Program Support 
For use at the discretion of 
the President and Trustees ............................ 9,000,000 
Facilities 
Modernization and renovation of 
laboratories, hospital, and 
essential support services ........................... 15,000,000 
Total for Program Support and Capital Projects ............ $79,000,000 
Grand Total ................................ $150,000,000 
32 The Rockefeller University 
is not known at this time and will not be for many months. 
Nevertheless, it is the most far-reaching tax legislation in many 
years, and the uncertainty about its eventual impact on philanthropy 
is cause for careful attention and concern. Increased cost of housing 
in New York City, the need to modernize older laboratories, con­
tinuing inflation, and the signs of national economic downturn are 
further causes for concern. 
On the positive side, our development efforts, begun so carefully 
by my predecessor Frederick Seitz a decade ago with almost no pre­
vious history of institutional donors, this year reached an annual 
level of $15 million in new gifts and pledges, with a momentum sug­
gesting further growth. Most important, the demonstrable excel­
lence of basic research and teaching at The Rockefeller University 
marks it as one of the best opportunities for philanthropic "invest­
ment." 
The ultimate success of the Development Program rests on our 
ability to identify, involve, and communicate with an expanding 
constituency of individuals, corporations, and foundations. To ac­
complish this, we are enlarging our programs of campus visits by in­
dividuals and groups who can speak for the University and contri­
bute to its financial well-being. This progress is augmented by a con­
tinuing series of regional meetings and an increasing variety of 
University publications. In summary, I am optimistic of achieving 
our $150-million goal in good time for the 1988 target. 
Finally, my sincere thanks, on behalf of the trustees and the 
campus community, to all of our donors, and to the volunteers who 
conduct our programs. Without this material manifestation of wide­
ly based, public-spirited support from private individuals and organ­
izations, we could not hope to meet our obligations to the welfare of 
humankind. 
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Gifts and Grants 
The University's Development Program seeks $150 million by the 
end of 1988.' The goals emphasize additional endowment and long­
term operating support for basic research in the life sciences, clinical 
programs of our hospital, endowed professorships, predoctoral and 
postdoctoral fellowships, and the renovation of research facilities. 
The following pages include two lists of donors for the current 
two-year period. List I represents individuals, foundations, corpora­
tions, and bequest gifts contributing to general goals. List II 
comprises governmental and private sponsors of special projects. 
Listi 
Individuals 
Mr. Ralph E. Ablon 
Mr. and Mrs. Frederick L. Adler 
Ms. Hope Aldrich 
Anonymous 
Mrs. Vincent Astor 
Mr. Robert Bach 
Mr. Albert M. Baer 
AlexanderG. Beam, M.D. 
Mr. George F. Bennett 
Mr. Richard Bernheim 
The Boorstein Family Fund 
Mr. William Braden 
Mr. Frank T. Cary 
Mr. and Mrs. Lauristan Castleman 
Mr. and Mrs. Eliot C. Clarke 
Mr. and Mrs. Farnham Collins 
Mr. and Mrs. Joseph C. Cornwall 
Mr. Granger Costikyan 
Mrs. Susan L. Cullman 
Mr. Joseph H. Davenport, Jr. 
Mr. and Mrs. Nicholas F. Deak 
Eli Whitney Debevoise, Esq. 
Mr. and Mrs. J. Richardson Dilworth 
Mr. Eugene F. Di Paola 
Mr. Frank D. Orang 
Mr. and Mrs. Barry W. Dress 
Ms. Peggy Dulany 
Mr. Royal H. Durst 
Anne E. Dyson, M.D. 
Mr. and Mrs. Charles H. Dyson 
Mr. Burtt R. Ehrlich 
Mr. and Mrs. Peter Elder 
Mr. Manuel Espinosa Yglesias 
Ms. Sandra Ferry 
Mr. and Mrs. Edward S. Finkelstein 
Mr. Richard Flender 
Alexander D. Forger, Esq. 
Mr. and Mrs. Leonard Franklin 
Mrs. Ann Haebler Frantz 
Mrs. Verena Frauenfelder 
Mr. Richard M. Furlaud 
Dr. and Mrs. John R. Gamble 
Mr. and Mrs. Edward L. Gardner 
Dr. Eugene Garfield 
Mr. Patrick J. Garvey 
Mr. Carl Gerstacker 
Mr. Seth Glickenhaus 
Mr. Roger J. Goebel 
Mr. and Mrs. William T. Golden 
Mr. Albert S. Goldman 
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In memory of Ethel Goldstein 
Mr. Leon Gould 
Dr. and Mrs. William C. Greenough 
In memory of Flora E. Griffin 
Mr. and Mrs. Patrick E. Haggerty 
Mr. Neil Hanlon 
Mrs. Pamela Harriman 
Mr. Michael Harris 
Ms. Maxine Harrison 
Mrs. Helen H. Harrower 
Mr. Martin Heilbrunn 
Mrs. Marian S. Heiskell 
Mr. Christian A. Herter, Jr. 
Mr. Carl B. Hess 
Mr. Leon Hess 
Mrs. Theodore Hetzler 
Mr. and Mrs. Clifton H. Hipkins 
Ms. Neva Kaiser 
Mr. and Mrs. Samuel T. Kantor 
Mr. Bernard Laterman 
Mr. and Mrs. Jonathan E. Lazrus 
Dr. and Mrs. Joshua Lederberg 
Mr. H. W. Lee 
Mr. Frederick G. Lehmann 
Dr. and Mrs. Louis Lehrman 
Mr. Martin L. Leibowitz 
Ms. Catherine Levin 
Dr. Philip Levine 
Mr. and Mrs. Budd Levinson 
Mr. Gustav 0. Lienhard 
Mr. Harold F. Linder 
Mr. and Mrs. James A. Linen III 
Mr. Edmund W. Littlefield 
Mr. Henry Luce III 
Mr. Ira H. Lustgarten 
John E. MacKenty, Esq. 
Mr. Cyril Magnin 
Mrs. Lucille Markey 
Mr. John McCarthy 
Dr. and Mrs. Maclyn McCarty 
Dr. Ray McDermott 
Richard Menaker, Esq. 
Mr. and Mrs. Herman I. Merinoff 
Mrs. Maurice Moore 
Mr. Louis Moskowitz 
Mr. RodneyW. Nichols 
Mr. Albert L. Nickerson 
In memory of Alfred Nogi 
Mr. Suliman Olayan 
Mr. and Mrs. George D. O'Neill 
SirY. K. Pao 
Mr. and Mrs. Thomas Parsons III 
Mr. Lowell R. Patton, Jr. 
Mr. Bernard Petrie 
Mr. and Mrs. Harvey Picker 
Mr. and Mrs. Jaime Raventos Vinal 
Mr. and Mrs. Robert J. Ravitz 
Mr. Gustave A. Reh, Jr. 
Mrs. Helene 0. Rittenberg 
Mr. Edward Robinson 
Mr. David Rockefeller 
Mrs. Doris L. Rosenberg 
Mr. Samson Rosenblatt 
Mr. Eric D. Rosenfeld 
Mr. Richard Rosenthal 
Mr. Fayez Sarofim 
Mr. Morris M. Schrier 
Mr. and Mrs. Daniel Schwartz 
Mr. David C. Scott 
Dr. and Mrs. Frederick Seitz 
Mr. and Mrs. Phillip Shatz 
Mr. and Mrs. Masood R. Siddiqi 
Ms. Abby Simpson 
Mr. and Mrs. Herbert M. Singer 
Mr. and Mrs. Malcolm Smith 
William R. Soons, Esq. 
Mr. Maury L. Spanier 
Mr. Michael A. Steiber 
Mr. and Mrs. James A. Stern 
Mrs. Lenore 0. Stern 
John R. Stevenson, Esq. 
Mr. and Mrs. J. Paul Sticht 
Ms. Jennifer Stone 
Mr. RobertG. Stone, Jr. 
Mrs. Clementine M. Tangeman 
Mr. and Mrs. James F. Thacher 
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Count and Countess 
W. A. W. van Limburg Stirum 
Mr. RobertL. Van Valer 
Mr. DeWitt Wallace 
Mr. Lew Wasserman 
Dr. W. Gordon Whaley 
Mr. Edwin C. Whitehead 
Mr. and Mrs. Julius Wile 
James R. Withrow, Jr., Esq. 
Mr. Lester Wolfe 
Mrs. Thew Wright 
Mr. Wilfred Wyler 
Dr. and Mrs. Richard S. Young 
Dr. Chen Ning Yang 
In memory of Anna Zizzo 
Foundations 
Achievement Rewards for College 
Scientists (ARCS) Foundation, Inc. 
Harriett Ames Charitable Trust 
Archbold Charitable Trust 
The Vincent Astor Foundation 
The Robert and Ellen Bach 
Foundation,lnc. 
Benwood Foundation 
Edith C. Blum Foundation 
Brayton-Wilbur Foundation 
Carrier Foundation 
Mary Flagler Cary Charitable Trust 
Centennial Foundation 
Leo W. and Lilyan E. Cole Fund 
The Commonwealth Fund 
Constans Culver Foundation 
Dresser Foundation 
Camille and Henry Dreyfus 
Foundation, Inc. 
Dyson Foundation 
Ferdinand Eberstadt Foundation 
Blanche D. Enders Trust 
The Charles W. Engelhard Foundation 
Sherman Fairchild Foundation, Inc. 
Max C. Fleischmann Foundation 
Erwin 0. and Rosalind H. Freund 
Foundation 
Fund for Higher Education 
Herman Goldman Foundation 
Hagedorn Fund 
Irma T. Hirschl Charitable Trust 
Jephson Educational Trust 
Jonsson Foundation 
Kimmelman Foundation 
The Kresge Foundation 
Landegger Charitable Fund 
Florina Lasker Charitable Trust 
Samuel & Ethel Lefrak Foundation 
Lem berg Foundation, Inc. 
The Leonhardt Foundation 
Dorothea Leonhardt Fund of 
Communities Foundation of Texas 
Leonhardt Fund of the New York 
Community Trust 
Thayer Lindsley Trust 
George Link Jr. Foundation, Inc. 
Richard Lounsbery Foundation 
Virginia and Leonard Marx Foundation 
The McKnight Foundation 
Andrew W. Mellon Foundation 
Edward S. Moore Foundation, Inc. 
The Perkin Fund 
The Pew Memorial Trust 
Harold and Beatrice Renfield Foundation 
Charles H. Revson Foundation 
Fannie E. Rippel Foundation 
Rockefeller Brothers Fund 
The Rockefeller Foundation 
Billy Rose Foundation 
Dorothy and Benjamin Rosenbloom 
Foundation 
Jon and Sue Rotenstreich Foundation 
The Lewis and Marcia Schott Foundation 
The Seth Sprague Educational 
and Charitable Foundation Inc. 
Jules and Doris Stein Foundation 
The Tubman Trust 
Wasserman Foundation 
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Arthur K. Watson Charitable Trust 
Nina W. Werblow Charitable Trust 
Harry Winston Research Foundation, Inc. 
The Norman and Rosita Winston 
Foundation 
Corporations 
Air Products and Chemicals, Inc. 
Allied Corporation 
Allied Chemical Foundation 
Allis-Chalmers Foundation, Inc. 
American Broadcasting Companies, Inc. 
American Industrial Health Council 
American Telephone 
& Telegraph Company 
AMF Incorporated 
Amoco Foundation, Inc. 
Atlantic Richfield Foundation 
Bomack International Marketing 
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